Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice ® CDx ...

A new ovarian cancer surveillance test is now being offered to women with an inherited risk of the disease, marking a significant development in care. University College London Hospitals NHS ...

Myriad Genetics received approval for a diagnostic test aimed at identifying advanced ovarian cancer patients eligible for treatment with Zejula from the Food and Drug Administration.

BRCA gene mutations can significantly raise a woman’s risk of breast and ovarian cancer. Know how hereditary cancer risk works and why genetic testing and early screening matter.

Myriad Genetics receives US FDA approval for MyChoice CDx test as companion diagnostic for Zejula for patients with ovarian cancer: Salt Lake City Thursday, March 19, 2026, 15:00 ...

Add Yahoo as a preferred source to see more of our stories on Google. Ovarian cancer is usually diagnosed using a mix of scans and blood tests (Getty/iStock) A straightforward blood test shows promise ...

Eligible patients can receive up to 70 per cent in subsidies for genetic tests, while MediShield Life coverage will be extended to selected risk-reducing surgical procedures.

Only 23.3% of ovarian cancer patients receive BRCA testing, leading to higher treatment costs and advanced therapy lines. Non-White and low-income patients face increased financial toxicity, ...

RHY’s geneType twice as effective at identifying women with elevated ovarian cancer risk than using clinical or genetic information alone Peer-reviewed study validates Rhythm’s ovarian cancer risk ...

Women with an inherited risk of developing ovarian cancer because they have the so-called Angelina Jolie gene alteration can now be tested on the NHS thanks to UCL research. University College London ...

Australian scientists have created a blood test to guide more effective ovarian cancer treatment, by identifying the women more likely to respond to an ovarian cancer treatment known as PARP inhibitor ...

Sept. 12 -- FRIDAY, Sept. 11 (HealthDay News) -- The U.S. Food and Drug Administration has approved a new test for women with pelvic tumors that are known to need surgery. The test, called OVA1, will ...